Esperion Therapeutics

Daiichi torches Esperion’s Nexletol milestone promises
Daiichi torches Esperion’s Nexletol milestone promises
EP Vantage
Daiichi Sankyo
Esperion Therapeutics
Nexletol
Flag link:
ACC 2023 – Esperion’s outcomes win looks lacklustre
ACC 2023 – Esperion’s outcomes win looks lacklustre
EP Vantage
Esperion Therapeutics
ACC
Nexletol
cholesterol
Flag link:
Catalysts ahead for the smaller players
Catalysts ahead for the smaller players
EP Vantage
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
Flag link:
End-of-Year Restructuring Means Layoffs for These Companies
End-of-Year Restructuring Means Layoffs for These Companies
BioSpace
restructuring
Rigel Pharmaceuticals
Zymergen
Esperion Therapeutics
Amarin
Theravance
Sanofi
Acorda Therapeutics
CureVac
Ziopharm Oncology
Flag link:
Esperion gets out the budget ax, chopping 170 staffers as its big drug launch sputters
Esperion gets out the budget ax, chopping 170 staffers as its big drug launch sputters
Endpoints
Esperion Therapeutics
layoffs
FDA
Nexletol
bempadoic acid
Flag link:
What if a pill could lower cholesterol like pricey injectables? Esperion intends to find out
What if a pill could lower cholesterol like pricey injectables? Esperion intends to find out
Stat
Esperion Therapeutics
cholesterol
Serometrix
Flag link:
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod
Xconomy
Esperion Therapeutics
FDA
bempedoic acid
Flag link:
Esperion shifts to show not tell
Esperion shifts to show not tell
EP Vantage
Esperion Therapeutics
bempedoic acid
Nexletol
Flag link:
Esperion adds more competition to cholesterol drug market with newly approved drug
Esperion adds more competition to cholesterol drug market with newly approved drug
BioPharma Dive
Esperion Therapeutics
cholesterol
bempedoic acid
FDA
Nexletol
Flag link:
Go or no go? Esperion's double whammy and a look to priority reviews
Go or no go? Esperion's double whammy and a look to priority reviews
EP Vantage
FDA
Esperion Therapeutics
Acacia Pharma
Blueprint Medicines
Agile Therapeutics
Lundbeck
Sun Pharma
Biohaven
Durect Corporation
Flag link:
Biotech's Most Volatile Binary Events for Q1
Biotech's Most Volatile Binary Events for Q1
Motley Fool
FDA
Esperion Therapeutics
Karyopharm
TG Therapeutics
Heron Therapeutics
Flag link:
Esperion's cholesterol-lowering drug clears test in diabetics
Esperion's cholesterol-lowering drug clears test in diabetics
Fierce Biotech
Esperion Therapeutics
type 2 diabetics
bempedoic acid
Flag link:
Eyeing a drug launch in early ’20, Esperion lines up a new, $200M funding deal
Eyeing a drug launch in early ’20, Esperion lines up a new, $200M funding deal
Endpoints
Esperion Therapeutics
bempadoic acid
drug launches
Flag link:
Here's Why Esperion Therapeutics Shares Rocketed 11.5% Higher Today
Here's Why Esperion Therapeutics Shares Rocketed 11.5% Higher Today
Motley Fool
Esperion Therapeutics
bempedoic acid
FDA
Flag link:
Esperion’s cholesterol-lowering pill works when statins fail
Esperion’s cholesterol-lowering pill works when statins fail
Pharmaforum
Esperion Therapeutics
cholesterol
statins
bempedoic acid
Flag link:
Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market
Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market
Endpoints
Daiichi Sankyo
Esperion Therapeutics
Flag link:
What's Next for Esperion Therapeutics' Cholesterol-Lowering Drug
What's Next for Esperion Therapeutics' Cholesterol-Lowering Drug
Motley Fool
Esperion Therapeutics
bempedoic acid
cholesterol
Flag link:
A new drug lowers cholesterol. Can it spoil a multibillion-dollar market?
A new drug lowers cholesterol. Can it spoil a multibillion-dollar market?
Stat
Esperion Therapeutics
bempedoic acid
LDL cholesterol
Flag link:
Highly anticipated trial results expected soon could move all three of these biotechs
Highly anticipated trial results expected soon could move all three of these biotechs
Motley Fool
Sangamo Therapeutics
Esperion Therapeutics
Loxo Oncology
SB-913
bempedoic acid
LOXO-292
Flag link:
Esperion's Cholesterol Combo Pill Cuts Bad Cholesterol 35%
Esperion's Cholesterol Combo Pill Cuts Bad Cholesterol 35%
Forbes
Esperion Therapeutics
bempedoic acid
statins
Zetia
Merck
cholesterol
Flag link:

Pages